Selective endothelin ETA and dual ETA/ETB receptor blockade improve endothelium-dependent vasodilatation in patients with type 2 diabetes and coronary artery disease

Life Sciences

Volumn 118, Issue 2, 2014, Pages 435-439

  Rafnsson, Arnar ^a   Shemyakin, Alexey ^a   Pernow, John ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Coronary artery disease; Diabetes mellitus; Endothelial dysfunction; Endothelin a receptor; Endothelin b receptor; Endothelin receptor antagonist; Endothelin 1; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NITRIC ACID DERIVATIVE; NITROPRUSSIDE SODIUM; ORAL ANTIDIABETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; OXYGEN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENTING; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; FOREARM; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; INSULIN TREATMENT; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT HISTORY OF CORONARY ARTERY BYPASS GRAFT; PERCUTANEOUS CORONARY INTERVENTION; SINGLE BLIND PROCEDURE; TRANSCUTANEOUS OXYGEN MONITORING; VASCULAR ENDOTHELIUM; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY; BLOOD FLOW; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; LASER DOPPLER FLOWMETRY; METABOLISM; PATHOPHYSIOLOGY; PLETHYSMOGRAPHY; PRESSURE; RANDOMIZED CONTROLLED TRIAL; SKIN; VASCULARIZATION;

CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; ENDOTHELIN RECEPTOR ANTAGONISTS; ENDOTHELIUM, VASCULAR; HUMANS; LASER-DOPPLER FLOWMETRY; MIDDLE AGED; OXYGEN; PARTIAL PRESSURE; PLETHYSMOGRAPHY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; REGIONAL BLOOD FLOW; SKIN; VASODILATION;

EID: 84897121117     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2014.02.026     Document Type: Article

References (16)

1. Creager, M.A., Luscher, T.F., Cosentino, F., Beckman, J.A., Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 108 (2003), 1527–1532.
2. Iwasa, S., Fan, J., Shimokama, T., Nagata, M., Watanabe, T., Increased immunoreactivity of endothelin-1 and endothelin B receptor in human atherosclerotic lesions. A possible role in atherogenesis. Atherosclerosis 146 (1999), 93–100.
3. Lerman, A., Zeiher, A.M., Endothelial function: cardiac events. Circulation 111 (2005), 363–368.
4. Li, W., Sachidanandam, K., Ergul, A., Comparison of selective versus dual endothelin receptor antagonism on cerebrovascular dysfunction in diabetes. Neurol Res 33 (2011), 185–191.
5. Moreno, P.R., Fuster, V., New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 44 (2004), 2293–2300.
6. Pernow, J., Shemyakin, A., Bohm, F., New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. Life Sci 91 (2012), 507–516.
7. Rafnsson, A., Bohm, F., Settergren, M., Gonon, A., Brismar, K., Pernow, J., The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. Diabetologia 55 (2012), 600–607.
8. Reriani, M., Raichlin, E., Prasad, A., et al. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 122 (2010), 958–966.
9. Rosato, E., Molinaro, I., Borghese, F., Rossi, C., Pisarri, S., Salsano, F., Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension. J Rheumatol 37 (2010), 2531–2539.
10. Settergren, M., Bohm, F., Ryden, L., Pernow, J., Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J 29 (2008), 1753–1760.
11. Settergren, M., Pernow, J., Brismar, K., Jorneskog, G., Kalani, M., Endothelin-A receptor blockade increases nutritive skin capillary circulation in patients with type 2 diabetes and microangiopathy. J Vasc Res 45 (2008), 295–302.
12. Shemyakin, A., Bohm, F., Wagner, H., Efendic, S., Bavenholm, P., Pernow, J., Enhanced endothelium-dependent vasodilatation by dual endothelin receptor blockade in individuals with insulin resistance. J Cardiovasc Pharmacol 47 (2006), 385–390.
13. Shemyakin, A., Salehzadeh, F., Bohm, F., et al. Regulation of glucose uptake by endothelin-1 in human skeletal muscle in vivo and in vitro. J Clin Endocrinol Metab 95 (2010), 2359–2366.
14. Shemyakin, A., Salehzadeh, F., Esteves Duque-Guimaraes, D., et al. Endothelin-1 reduces glucose uptake in human skeletal muscle in vivo and in vitro. Diabetes 60 (2011), 2061–2067.
15. Shemyakin, A., Kovamees, O., Rafnsson, A., et al. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation 126 (2012), 2943–2950.
16. Takahashi, K., Ghatei, M.A., Lam, H.C., O'Halloran, D.J., Bloom, S.R., Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 33 (1990), 306–310.